Americas Lead Testosterone Replacement Therapy Market Share (79%) - Expected to Remain Major TRT Market Till 2020

USA - English

• India - English

PUNE, India, August 12, 2016 /PRNewswire/ --

The global testosterone replacement therapy market 2016-2020 research report says entry of SARMs will be a key trend as testosterone therapies available as injectable or skin delivery formulations are currently used as androgen therapies. However, they are associated with side effects related to fluctuations in testosterone levels. The development and entry of SARMs in the market will serve as a better treatment option for androgen deficiencies. These drugs are available as orally active formulations and target androgen receptors specifically, thus eliciting the desired response in the body.

Complete report on testosterone replacement therapy market spread across 59 pages, analyzing 4 major companies and providing 33 data exhibits now available at http://www.sandlerresearch.org/global-testosterone-replacement-therapy-market-2016-2020.html.

Topical drugs dominate the global testosterone replacement therapy market when compared to oral and injectable formulations. The increased awareness among the general public about endocrine disorders and the latest medical advancements and treatment options available will aid to the market during the forecast period. Several organizations such as the Testicular Cancer Awareness Foundation are also helping individuals in the early detection and treatment of the diseases, which may occur due to decreased testosterone levels in the body.

The testosterone replacement therapy market in the Americas is declining at a substantial CAGR of close to 15% to drop from USD 2 billion to USD 0.9 billion by 2020. However, despite the decline, Americas will remain the major market for testosterone replacement therapy during the forecast period. The testosterone replacement therapy market in EMEA was valued at USD 370 million in 2015 and is expected to exceed USD 745 million by 2020, growing at a CAGR of over 15%. Western Europe, including France, Germany, Italy, Spain, and the UK, contributed significantly to the overall growth of the market in 2015. The testosterone replacement therapy market in APAC was valued at USD 170 million in 2015 and is expected to reach USD 510 million by 2020, growing at a CAGR of over 24%. APAC remains the fastest growing market due to the growing awareness about the disease along with the rise in healthcare spending in this region.

The analyst forecast global testosterone replacement therapy market is gradually declining. According to the report, increase in older population will be a key driver for testosterone replacement therapy market stability. Age related lowering of testosterone presents features both primary and secondary hypogonadism. Improved healthcare infrastructure and sophisticated treatment facilities have increased life expectancy of individuals. This has led to an increase in older adult population worldwide.

The following companies are the key players in the global testosterone replacement therapy market: AbbVie, Allergan, Eli Lilly, and Endo International. Other prominent vendors in the market are: Acerus Pharmaceuticals, Antares Pharma, Bayer HealthCare Pharmaceuticals, Bedford Labs, Clarus Therapeutics, Ferring Pharmaceuticals, Forendo Pharma, Juniper Pharmaceuticals, Lipocine, MetP Pharma, Mylan, Pfizer, ProStrakan, Repros Therapeutics, Sandoz, TesoRx, and Teva Pharmaceuticals. Order a copy of Global Testosterone Replacement Therapy Market 2016-2020 report @ http://www.sandlerresearch.org/purchase?rname=58502.

Global Testosterone Replacement Therapy Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report includes a discussion of the key vendors operating in this market. This report covers the present scenario and the growth prospects of the global testosterone replacement therapy market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs that treat and prevent hypogonadism.

Another related report is Global Non-alcoholic Steatohepatitis Market 2016-2020; one noteworthy trend in the market is the availability of patient assistance programs. Patient assistance programs offered by vendors, designed to fit individual needs regarding liver diseases, help them attain access to medications. AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, and Novo Nordisk are among the companies that offer patient assistance programs, offering solutions such as co-pay assistance and coupons. Browse complete report @ http://www.sandlerresearch.org/global-non-alcoholic-steatohepatitis-market-2016-2020.html.

Explore other new reports on Therapeutics Market @ http://www.sandlerresearch.org/market-research/pharmaceutical/therapeutics.

About Us: 

SandlerResearch.org is your go-to source for all market research needs. Our database includes thousands of market research reports from over multiple leading global publishers & in-depth market research studies of over several micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+1 888 391 5441
[email protected]

Connect with Us: 
G+ / Google Plus: https://plus.google.com/106598308303011242341/posts
Twitter: https://twitter.com/SandlerResearch
Facebook: https://www.facebook.com/pages/Sandler-Research/524957830948790
YouTube: https://www.youtube.com/channel/UCCQLoqvZE2Py7AxNeNlBXoA
Pinterest: https://www.pinterest.com/SandlerResearch/

SOURCE Sandler Research